Zimmer Partners’s Aktis Oncology AKTS Stock Holding History

Zimmer Partners’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$268K	–	163
2026 Q1	$268K	Buy	+15,000	New	+$291K	0.01%	120

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Zimmer Partners's AKTS Position: Q2 2026 in Review

Zimmer Partners sold out of Aktis Oncology (AKTS) in Q2 2026, closing a stake of 15,000 shares — an estimated $268K sold.

Zimmer Partners first reported a position in AKTS in Q1 2026 and held it in 1 quarter. The position peaked at $268K in Q1 2026. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Zimmer Partners reported no remaining Aktis Oncology position as of Q2 2026 after selling out during the quarter.
Zimmer Partners sold 15,000 Aktis Oncology shares in Q2 2026, an estimated $268K.
Zimmer Partners first reported a position in Aktis Oncology in Q1 2026 and held it in 1 quarter.
Zimmer Partners's Aktis Oncology position peaked at $268K in Q1 2026.
113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Zimmer Partners's 13F filing for Q2 2026, filed 14 Aug 2026.